No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 9
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Liminatus Pharma, Inc. Class A Common Stock (LIMN) stock was $3.81 as of Oct 6, 2026, 2:30 PM EDT, down 4.51% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -95.3%
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer.
Biotechnology · Cerritos, CA
LATEST PRICE
$3.81
52-WEEK RANGE
$3.29 - $141.50
BETA
0.71
% FROM 52W HIGH
-97.31%
MARKET CAP
$5.12M
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
N/A
PE RATIO (FWD)
forward FY estimate
N/A
P/B RATIO
17.02
P/S RATIO
TTM
N/A
P/OCF RATIO
TTM
N/A
EV/EBITDA
TTM
N/A
DEBT / EQUITY
4.80
REVENUE TTM
$0
GROSS MARGIN TTM
0.00%
NET PROFIT MARGIN TTM
0.00%
REVENUE GROWTH TTM
TTM vs prior TTM
N/A
REVENUE CAGR 3Y
N/A
REVENUE CAGR 5Y
N/A
TTM TOTAL RETURN
-95.32%
3Y TOTAL RETURN
annualized (CAGR)
N/A
5Y TOTAL RETURN
annualized (CAGR)
N/A
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.50
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$3.81
High
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LIMN | $5.12M | $3.81 | -4.51% | -95.32% | N/A | N/A | N/A |
| 2BMGL | $5.04M | $3.22 | +1.58% | -83.45% | N/A | N/A | vs LIMN |
| 3ALZN | $5.20M | $1.37 | -3.04% | -44.11% | -79.14% | N/A | vs LIMN |
| 4IMNN | $5.03M | $1.20 | -3.56% | -76.74% | -63.83% | -55.17% | vs LIMN |
| 5LNAI | $5.21M | $1.15 | +0.88% | -88.84% | N/A | N/A | vs LIMN |
| 6GELS | $5.21M | $0.57 | +4.47% | -57.02% | N/A | N/A | vs LIMN |
N/A
